Free Trial
NASDAQ:ELYM

Eliem Therapeutics (ELYM) Stock Price, News & Analysis

Eliem Therapeutics logo
$1.95 -0.06 (-2.99%)
As of 01/17/2025

About Eliem Therapeutics Stock (NASDAQ:ELYM)

Key Stats

Today's Range
$1.91
$2.05
50-Day Range
$1.80
$4.06
52-Week Range
$2.35
$11.55
Volume
141,882 shs
Average Volume
486,688 shs
Market Capitalization
$58.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Receive ELYM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ELYM Stock News Headlines

Ignore every stock…
Stocks have been on a tear in 2024… And there’s plenty of great opportunities out there. But one expert says you should forget about EVERY stock for a moment and focus on an even bigger opportunity. The current GOLD supercycle You see, stocks are a dime a dozen for the most part… And, fortunately, they go up more than they go down. But every few decades, precious metals have a systematic supercycle that tends to dwarf the potential of just about anything else. The last time things aligned like this on gold it surged 536%
See More Headlines

ELYM Stock Analysis - Frequently Asked Questions

Eliem Therapeutics' stock was trading at $1.80 at the start of the year. Since then, ELYM stock has increased by 8.3% and is now trading at $1.95.
View the best growth stocks for 2025 here
.

Eliem Therapeutics, Inc. (NASDAQ:ELYM) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.70) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.19.

Eliem Therapeutics (ELYM) raised $75 million in an initial public offering on Tuesday, August 10th 2021. The company issued 6,000,000 shares at a price of $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO.

Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eliem Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
11/08/2021
Today
1/21/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELYM
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Net Income
$-35,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.90 per share

Miscellaneous

Free Float
28,354,000
Market Cap
$58.02 million
Optionable
Not Optionable
Beta
-0.39
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ELYM) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners